Last €113.50 EUR
Change Today -1.90 / -1.65%
Volume 3.2M
BAYN On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 10:06 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAYN) Snapshot

Open
€116.15
Previous Close
€115.40
Day High
€116.65
Day Low
€112.45
52 Week High
12/2/14 - €121.40
52 Week Low
04/15/14 - €89.49
Market Cap
93.7B
Average Volume 10 Days
2.9M
EPS TTM
€4.42
Shares Outstanding
826.9M
EX-Date
04/30/14
P/E TM
25.6x
Dividend
€2.10
Dividend Yield
1.86%
Current Stock Chart for BAYER AG-REG (BAYN)

bayer ag-reg (BAYN) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAYN) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as contraceptives, hemophilia treatments, anticoagulants, and medicines to treat multiple sclerosis, cancer, hypertension, and infectious diseases; and consumer health products comprising over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; contrast agent injection systems for diagnostic and therapeutic medical procedures in computed tomography, magnetic resonance imaging, and molecular imaging; and mechanical systems for removing thrombi from blood vessels, as well as service products for its systems. The CropScience segment offers products for use in agriculture as insecticides, fungicides, and herbicides or seed treatments; seeds and plant traits; and various products for gardens, green industry, and nonagricultural pest control. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and functional films; and produces and markets inorganic basic chemicals. The company has a strategic alliance with OncoMed Pharmaceuticals, Inc. to develop drugs to target cancer stem cell therapeutics. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

115,416 Employees
Last Reported Date: 10/30/14
Founded in 1863

bayer ag-reg (BAYN) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €2.9M
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €1.8M
Labor Director and Member of Management Board
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

bayer ag-reg (BAYN) Key Developments

Bayer to Sell Equine Products to US Merial

Bayer AG has agreed to divest its equine products Legend/Hyonate and Marquis to US veterinary products maker Merial for an undisclosed price. The transaction is subject to approval by the relevant authorities and is expected to close in the first quarter of 2015. The products do not have strategic value for Bayer HealthCare's animal health division and account for less than 2% of the unit's worldwide sales.

Sanofi Not Interested In Acquiring Diabetes Device Business From Bayer

Sanofi (ENXTPA:SAN) is not interested in purchasing diabetes device business from Bayer AG (DB:BAYN). Serge Weinberg, interim Chief Executive Officer of Sanofi, stressed that Sanofi is not interested in purchasing Bayer’s diabetes device business.

Bayer AG Launches New Version of Radimetrics(TM)

Bayer AG unveiled version 2.5 of its Radimetrics(TM) Enterprise Platform. The enhanced version has new features that can help radiologists and hospital administrators meet new 2015 U.S. Joint Commission Diagnostic Imaging Standards, providing information to help optimize radiation dose management and contrast dose analytics to advance image quality and patient care. The new software is a next generation upgrade of the platform, which was the first single tool to manage both radiation dose and contrast dose analytics in computed tomography (CT). New features include more advanced contrast dose analytics and new charts and data options to help identify repeat injections and issues associated with intravenous administration. Enhancements include the ability to align customers' various protocol names to standardized naming conventions from the RadLex(R) Playbook and further expand capabilities in mammography and general X-ray modalities, improving analytics and workflow efficiencies. Everything can be analyzed in line with external benchmarks, helping administrators further standardize protocols and identify training needs across all enterprise sites. The use of radiation in medicine has led to vast improvements in the diagnosis and treatment of diseases and patient care. Each year, there are more than 3.5 billion X-ray examinations performed worldwide and more than 85 million CT examinations performed in the U.S. Health authorities and policy makers, such as the U.S. Joint Commission, are increasingly evaluating the risk-benefit profile of patient exposure to ionizing radiation. Radimetrics Enterprise Platform: Bayer's Radimetrics(TM) Enterprise Platform merges and mobilizes patient dose histories and current exam details across all enterprise sites, bringing analysis and quality solutions to the point of care. This platform provides both radiation dose management and contrast dose analytics management and rapid access to patient dose history. Quality tools at every phase of the workflow let administrators, radiologists, technologists and medical physicists interact with and share dashboards to conduct clinical and operational analyses on-demand.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYN:GR €113.50 EUR -1.90

BAYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $168.59 USD +0.11
Merck & Co Inc $59.37 USD +0.39
Pfizer Inc $31.83 USD -0.14
Sanofi €74.65 EUR -1.52
Dow Chemical Co/The $45.96 USD +0.48
View Industry Companies
 

Industry Analysis

BAYN

Industry Average

Valuation BAYN Industry Range
Price/Earnings 25.1x
Price/Sales 2.2x
Price/Book 4.5x
Price/Cash Flow 25.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.